From the 1Gynuity Health Projects, New York, New York; 2Magee Womens Hospital/University of Pittsburgh, Pittsburgh, Pennsylvania; 3Planned Parenthood of Waco, Waco, Texas; 4Planned Parenthood League of Massachusetts, Boston, Massachusetts; 5Whole Woman’s Health, Austin, Texas; 6Family Planning Associates Medical Group, Chicago, Illinois; 7Parkmed, New York, New York; and 8Institute for Urban Family Health, New York, New York.
Funds to carry out this study were provided by an anonymous donor.
The authors thank Thomas F. Britton, MD, Michael Molaei, MD, Robert Hanson, MD, and E. Steve Lichtenberg, MD, MPH, for clinical oversight of their respective study sites and Dr. Lichtenberg for his support in the design of the study and revision of the manuscript.
Presented at the National Abortion Federation’s Annual Meeting, Boston, MA, April 21–24, 2007; Reproductive Health 2007, Minneapolis, MN, September 26–29, 2007, and the 10th Congress of the European Society of Contraception, Prague, Czech Republic, April 30 to May 3, 2008.
Corresponding author: Ilana G. Dzuba, Gynuity Health Projects, 15 E. 26th Street, Suite 801, New York, NY 10010; e-mail: [email protected].
Financial Disclosure Dr. Winkoff, Ms. Dzuba, and Ms. Shannon are all with Gynuity Health Projects (New York, NY), who had a contract with Danco Laboratories, the distributor of mifepristone in the United States, to carry out Phase IV studies that are a part of Danco’s responsibility to the U.S. Food and Drug Administration. Dr. Creinin has received compensation from Danco Laboratories, LLC, for providing third-party telephone consultations to clinicians who seek expert advice on mifepristone. The other authors have no potential conflicts of interest to disclose.
